期刊文献+

红豆杉多糖对糖尿病大鼠的降血糖作用及机制研究 被引量:7

Study on the hypoglycemic effect of taxus polysaccharides on diabetic rats and its mechanism
下载PDF
导出
摘要 目的:探讨红豆杉多糖降血糖作用及机制。方法:STZ诱导大鼠糖尿病模型,分为糖尿病模型组、阳性药物对照组和红豆杉多糖组,另设阴性对照组,每组10只。阳性对照组和红豆杉多糖组分别灌服二甲双胍和红豆杉多糖,另两组灌服生理盐水。连续给药30d。检测大鼠胸腺、脾脏组织T-SOD、GSH-PX及MDA水平。结果:红豆杉多糖可降低糖尿病大鼠血糖,提高脾脏、胸腺组织T-SOD、GSH-PX活力,降低MDA含量。结论:红豆杉多糖可通过影响大鼠主要免疫器官抗氧化系统,发挥降血糖作用。 Objective:To investigate the hypoglycemic effect and mechanism of taxus polysaccharide.Methods:Forty adult SD rats were divided into the diabetes model group,the positive drug control group,the taxus polysaccharide group and the negative control group,with 10 rats in each group.The diabetic rat model was established by intraperitoneal injection of streptozotocin(STZ).The positive control group and the taxus polysaccharide group were given metformin and taxus polysaccharide,respectively,and the other two groups were given normal saline for 30 consecutive days.The levels of T-SOD,GSH-PX and MDA in rat thymus and spleen tissues were detected.Results:The activity of T-SOD and GSH-PX in thymus and spleen tissues of rats in the taxus polysaccharides group was significantly increased,while the content of MDA was significantly decreased,the difference was statistically significant.Conclusion:Taxus polysaccharides can improve the activity of T-SOD and GSH-PX in thymus and spleen tissues,reduce the content of MDA,and play a role in lowering blood glucose.
作者 史岩 王宇峰 郭丽娇 刘钦源 赵伟 SHI Yan;WANG Yufeng;GUO Li jiao;LIU Qinyuan;ZHAO Wei(School of Public Health, Jiamusi University, Jiamusi 154007, China)
出处 《黑龙江医药科学》 2020年第1期184-185,187,共3页 Heilongjiang Medicine and Pharmacy
基金 黑龙江自然科学基金,编号:No.C2015046 黑龙江省教育厅项目,编号:No.2016-KYYWF-0617 佳木斯大学校长创新创业基金,编号:No.xzyf2014-15 佳木斯大学研究生科技创新项目,编号:No.LZZ2015-026 省教育厅大学生创新创业训练计划项目,编号:201810222091。
关键词 糖尿病 南方红豆杉多糖 降血糖 diabetes taxus polysaccharide fall blood sugar
  • 相关文献

参考文献3

二级参考文献43

  • 11,Georgoulias, Crown JP.Increasing options in cancer therapy: current status and future prospects. Anti CancerDrugs, 1999,10(Suppl 1)∶S1
  • 22,Christian MC, Pluda JM, Ho PTC, et al. Promising new agents under development by thedivision of cancer treatment, diagnosis and centers of the national cancer institute.Semin Oncol, 1997, 24∶219
  • 33,Kollmannsberger C, Mross K, Jakob A, et al. Topotecan—a novel topoisomerase Iinhibitor: pharmacology and clinical experience. Oncology, 1999,56∶1
  • 44,Armand JP, Cunningham D, Cutsem E, et al. Clinical advances with topoisomerase Iinhibitors in gastrointestinal malignancies. Anti Cancer Drugs, 1999, 10(Suppl 12)∶S5
  • 55,Sandler A, Oosterom AT. Irinotecan in cancer of the lung and cervix. Anti CancerDrugs, 1999, 10(Suppl 1)∶S13
  • 66,Redinbo MR, Stewart L, Kuhn P, et al. Crystal structure of human topoisomerase I incovalent and noncovalent complexes with DNA. Science, 1998,279∶1504
  • 77,Stewart L, Redinbo MR, Qiu X, et al. A model for the mechanism of human topoisomeraseI. Science, 1998,279∶1534
  • 88,Kraus-Berthier L, Guilband N, Jan M, et al. Experimental antitumor activity ofS-16020-2 in a panel of human tumors. Eur J Cancer, 1997,33∶1881
  • 99,Guilbaud N, Kraus-Berthier L, Saint-Dizier D, et al. In vivo antitumor activity ofs-16020-2, a new olivacine derivative. Cancer Chemother Pharmacol, 1996, 38∶513
  • 1010,Lemee S, Pierre A, Markovits J, et al. S-16020-2, a new highly cytotoxic antitumorolivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Mol Pharmacol,1998, 53∶213

共引文献45

同被引文献103

引证文献7

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部